Benzoyl Peroxide
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Benzoyl Peroxide: From Acne and Dermatitis to Vulvar Inverted Follicular Keratosis
One-Sentence Summary
Benzoyl peroxide is a topical agent originally used for acne and related inflammatory skin conditions. The TxGNN model predicts it may be effective for vulvar inverted follicular keratosis, but no clinical trials and no publications currently support this direction, so the prediction rests on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Acne, atopic eczema, contact dermatitis, seborrheic dermatitis, seborrheic keratosis, and related skin conditions (from the knowledge graph; the Singapore licence entries list no indication text) |
| Predicted New Indication | Vulvar inverted follicular keratosis |
| TxGNN Prediction Score | 99.92% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 2 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, benzoyl peroxide is a topical keratolytic and antimicrobial agent. It is established in acne and is linked in the knowledge graph to seborrheic keratosis, and mechanistically it may be applicable to related benign follicular lesions.
Inverted follicular keratosis is a benign lesion related to seborrheic keratosis, which is already among benzoyl peroxide's original indications. That relationship is the main reason the prediction looks plausible. However, the link is unverified. No studies have tested benzoyl peroxide at the vulvar site, where mucosal and skin irritation is a particular concern.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN15460P | EPIDUO FORTE GEL 0.3%/2.5% | Gel | Not stated in the data compiled for this report |
| SIN13789P | EPIDUO GEL 0.1%/2.5% | Gel | Not stated in the data compiled for this report |
Both products are topical gels and hold valid registrations.
Cytotoxicity
Benzoyl peroxide is not an antineoplastic drug, so this section does not apply.
Safety Considerations
- Knowledge-graph contraindication signals (from drug-disease association data, not package insert text): photosensitivity disease, dermatitis and exfoliative dermatitis, skin atrophy, telangiectasis and related vascular conditions, inflammatory bowel disease (including Crohn disease and ulcerative colitis), kidney disease, diabetes-related conditions, adrenocortical insufficiency, and anogenital or common warts. These should be verified against the official label.
- Site-specific concern: The predicted vulvar site involves mucosal and thin skin, where irritation risk is higher.
- Drug interactions: No interactions were found in the queried data.
For label-based warnings and contraindications, please refer to the package insert.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by the model score, with no trials or publications. The mechanistic link through seborrheic keratosis is plausible but untested, and irritation risk at the vulvar site is a concern. Other top predictions are weaker still: several have no plausible mechanism, and for phototoxic dermatitis the only literature describes the drug class as a cause of dermatitis. Acne keloid is the only other prediction with even indirect support, from an acne review that does not test benzoyl peroxide in this condition.
To proceed, the following is needed:
- Package insert warnings and contraindications from the Singapore regulator (HSA)
- Mechanism of action data from DrugBank
- Clinical or case-series evidence for benzoyl peroxide in inverted follicular keratosis, including tolerability at the vulvar site
- Assessment of formulation and route suitability, since the registered products are acne combination gels (benzoyl peroxide with a second active ingredient) rather than single-agent products
- Specialist dermatology or gynaecology review to confirm the diagnosis and the need for drug therapy, since the lesion is benign and other management options exist
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.